IM
IM8N.STU Insmed Incorporated
- Market cap
- EUR 22.1B
- P/E
- -
- P/B
- 33.98x
- ROE
- -50.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IM8N.STU undervalued?
Graham numberThe Graham number of Insmed Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Insmed Incorporated fundamental analysis
No fundamental analysis for Insmed Incorporated yet.
Insmed Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with br…
Full company profileInsmed Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Insmed Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 9.84M | 136M | 164M | 188M | 245M | 305M | 364M | 606M | 1.67B |
| Gross Profit | -87.3M | -67.6M | 7.41M | 112M | 125M | 144M | 190M | 240M | 278M | 483M | 1.42B |
| Operating Income | -173M | -189M | -307M | -235M | -265M | -368M | -478M | -681M | -787M | -995M | -511M |
| EBITDA | - | -184M | -294M | -217M | -250M | -384M | -449M | -660M | -819M | -1.18B | -261M |
| Net Income | -176M | -193M | -324M | -254M | -294M | -435M | -482M | -750M | -914M | -1.28B | -369M |
| EPS | - | -2.51 | -4.19 | -2.84 | -2.86 | -3.66 | -3.55 | -5.07 | -5.09 | -5.96 | -1.68 |
| Balance Sheet | |||||||||||
| Total Assets | 238M | 462M | 605M | 742M | 796M | 1.24B | 1.66B | 1.33B | 2.03B | 2.26B | 2.23B |
| Total Liabilities | 83.5M | 101M | 396M | 481M | 520M | 833M | 1.57B | 1.66B | 1.74B | 1.53B | 1.50B |
| Shareholders' Equity | 154M | 361M | 208M | 262M | 276M | 410M | 88.0M | -332M | 285M | 739M | 726M |
| Cash & Short-term Investments | 163M | 381M | 495M | 487M | 533M | 717M | 1.07B | 482M | 555M | 510M | 397M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -147M | -160M | -258M | -251M | -219M | -363M | -400M | -509M | -684M | -935M | -464M |
| Capital Expenditure | 4.20M | 3.00M | 13.1M | 42.3M | 6.24M | 7.29M | 9.88M | 15.8M | 21.9M | 32.6M | 20.5M |
| Free Cash Flow | - | -163M | -273M | -293M | -226M | -371M | -410M | -524M | -706M | -968M | -485M |
| Ratios | |||||||||||
| ROE | -114.1% | -53.4% | -155.7% | -97.2% | -106.6% | -105.9% | -547.5% | - | -320.2% | -172.8% | -50.9% |
| ROA | -74.1% | -41.7% | -53.6% | -34.3% | -36.9% | -35.0% | -29.1% | -56.4% | -45.1% | -56.4% | -16.6% |
| Net Profit Margin | - | - | -3,297.2% | -186.4% | -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% | -22.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Insmed Incorporated dividends
Insmed Incorporated has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Mar 3, 2011.
Who owns Insmed Incorporated
- Insiders 0.51%
- Institutions 99.49%
- Public & others 0.00%
- Shares outstanding 219M
- Free float 218M
Insmed Incorporated company profile
- Company name
- Insmed Incorporated
- Ticker
- IM8N.STU
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 912
- Fiscal year end
- December
- Address
- 700 US Highway 202/206, Bridgewater, NJ, United States, 08807
- Phone
- 908 977 9900
- Website
- insmed.com
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated management
1- Mr. William H. Lewis J.D., M.B.A.President, CEO & Chairman · born 1969